Jillian Renee Davenport, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 7700 Morro Rd, Atascadero, CA 93422 Phone: 805-466-6622 Fax: 805-461-0361 |
Laura Hutchison, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 7700 Morro Rd, Atascadero, CA 93422 Phone: 805-466-6622 Fax: 805-461-0361 |
Dr. James C. Tedford, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 7700 Morro Rd, Atascadero, CA 93422 Phone: 805-466-6622 Fax: 805-461-0361 |
Dr. Brian D. Patterson, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 7700 Morro Rd, Atascadero, CA 93422 Phone: 805-466-6622 Fax: 805-461-0361 |
Dr. Abiodun Olufemi Obadina, M.D., Pediatrics Medicare: Medicare Enrolled Practice Location: 10333 El Camino Real, Atascadero, CA 93422 Phone: 805-468-2000 |
Rosa Sanchez Rosen, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 7700 Morro Rd, Atascadero, CA 93422 Phone: 805-466-6622 |
News Archive
The GENCODE Consortium expects the human genome has twice as many genes than previously thought, many of which might have a role in cellular control and could be important in human disease. This remarkable discovery comes from the GENCODE Consortium, which has done a painstaking and skilled review of available data on gene activity.
It's a long-standing question: Can just the act of observing an experiment affect the results, According to a new study by Rockefeller University scientists, if the experiment uses a fluorescent dye called acridine orange, the answer is a resounding yes."
Time can be important in an emergency department especially in a busy Level 1 Trauma Center like MetroHealth Medical Center in Cleveland, when getting patients appropriate care is essential. However, when the quality of an emergency department is judged by a patient's length of stay, time takes on a new meaning.
Researchers at The Rockefeller University in New York have developed new tools to rapidly test the ability of antibodies to neutralize SARS-CoV-2, the novel coronavirus responsible for the COVID-19 pandemic.
Pfizer Inc today announced that the U.S. Food and Drug Administration (FDA) has issued a 90-day extension to the action date for the Company's supplemental Biologics License Application (sBLA) for use of Prevnar 13, in adults aged 50 and older.
› Verified 2 days ago